Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Receives $393.11 Consensus Target Price from Brokerages

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have earned an average recommendation of “Hold” from the twenty-four research firms that are presently covering the company, Marketbeat.com reports. Thirteen research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $395.32.

A number of equities research analysts recently issued reports on REGN shares. SunTrust Banks lifted their target price on Regeneron Pharmaceuticals to $400.00 and gave the company a “hold” rating in a research report on Friday, February 7th. ValuEngine raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, December 17th. Credit Suisse Group raised Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $400.00 target price on the stock in a research report on Friday, December 13th. Oppenheimer lifted their target price on Regeneron Pharmaceuticals from to and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, BidaskClub raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th.

Regeneron Pharmaceuticals stock traded up $0.74 during midday trading on Friday, reaching $399.55. The stock had a trading volume of 536,829 shares. The firm’s fifty day simple moving average is $370.46 and its 200-day simple moving average is $330.44. Regeneron Pharmaceuticals has a 1-year low of $271.37 and a 1-year high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $7.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $6.03 by $1.47. The firm had revenue of $2.17 billion during the quarter, compared to analyst estimates of $2.10 billion. During the same period in the prior year, the business posted $6.84 EPS. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals will post 24.94 EPS for the current year.

Regeneron Pharmaceuticals declared that its board has authorized a stock buyback program on Tuesday, November 5th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

In related news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $360.00, for a total transaction of $360,000.00. Following the transaction, the director now directly owns 11,323 shares of the company’s stock, valued at approximately $4,076,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $340.91, for a total value of $2,727,280.00. Following the transaction, the executive vice president now directly owns 57,751 shares in the company, valued at $19,687,893.41. The disclosure for this sale can be found here. Insiders have sold a total of 104,679 shares of company stock worth $38,681,248 in the last ninety days. Insiders own 11.84% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Evolution Wealth Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 2,100.0% in the 4th quarter. Evolution Wealth Advisors LLC now owns 66 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 63 shares during the period. Bridger Capital Management LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $30,000. Samalin Investment Counsel LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $37,000. Americana Partners LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $39,000. Finally, Barnett & Company Inc. boosted its stake in Regeneron Pharmaceuticals by 3,433.3% in the 4th quarter. Barnett & Company Inc. now owns 106 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 103 shares during the period. 66.42% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: What is an Initial Coin Offering (ICO)?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit